Abstract | OBJECTIVE: DESIGN: The study design was a two-group, randomized, double-blind, placebo-controlled trial. The patients with NAFLD were randomly assigned to receive δ- tocotrienol 300 mg twice daily or placebo for 24 weeks. ENDPOINTS: RESULTS: A total of 71 patients ( tocotrienol=35, placebo=36) were randomized and included in the intention to treat analysis. Compared with placebo, δ- tocotrienol significantly reduced (MD [95 % CI]) FLI (-8.52 [-10.7, -6.3]; p < 0.001); HOMA-IR (-0.37 [-0.53, -0.21]; p < 0.001), hs-CRP (-0.61[-0.81, -0.42]; p < 0.001), MDA (-0.91 [-1.20, -0.63]; p < 0.001), ALT (-8.86 [-11.5, -6.2]; p < 0.001) and AST (-6.6 [-10.0, -3.08]; p < 0.001). Hepatic steatosis was also reduced by a significantly greater extent with tocotrienol than with placebo (p =0.047). No adverse events were reported. CONCLUSION: TRIAL REGISTRATION: Sri Lankan Clinical Trials Registry (SLCTR/2015/023, 2015-10-03).
|
Authors | Muhammad Amjad Pervez, Dilshad Ahmed Khan, Atiq Ur Rehman Slehria, Aamir Ijaz |
Journal | Complementary therapies in medicine
(Complement Ther Med)
Vol. 52
Pg. 102494
(Aug 2020)
ISSN: 1873-6963 [Electronic] Scotland |
PMID | 32951743
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2020 Elsevier Ltd. All rights reserved. |
Chemical References |
- Biomarkers
- Vitamin E
- tocotrienol, delta
|
Topics |
- Adult
- Aged
- Biomarkers
(blood)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Non-alcoholic Fatty Liver Disease
(drug therapy)
- Vitamin E
(analogs & derivatives, therapeutic use)
- Young Adult
|